A Russian study to determine the severity and lethality of COVID-19 infection in patients with hematologic diseases
Description of the Study:
- Title: Registry of Patients With Hematologic Disease and COVID-19 in Russia (CHRONOS19).
- Principal Investigators: Olga A. Gavrilina, Kristina Zakurdaeva, Vladimir I. Vorobyev, Anastasia N. Vasileva, Lev S. Butaev, Alena Sukhareva, Lubov Gavrilova, Olga Samoylova, Maria Grishunina, Ochsana Ochirova, Alina Karpova, Olga Panteleeva, Mikhail A. Kunst, Vasily Shuvaev, Anzhelika Rakhmani, Tatiana V. Gaponova, Gennadiy M. Galstyan, Vera V. Troitskaya, Anton V. Luchkin, Elena N. Parovichnikova and Valery Savchenko.
- Center of Implementation: National Research Center for Hematology, Foundation for Cancer Research Support, Regional Clinical Hospital No1 (Ekaterinburg, Russian Federation), Republican Clinical Hospital of Tatarstan (Kazan, Russian Federation), City Hospital n.a. V.V. Veresaev (Moscow, Russian Federation), Clinical Hospital n.a. S.P. Botkin (Moscow, Russian Federation), Et al.
- Study Population: Patients with blood disease (both malignant and non-malignant) infected with SARS-CoV-2 infection, aged 18 or older.
- Study Type: Observational Prospective Cohort Study.
- Design: The primary measured outcome is 30-day all-cause mortality. And the secondary measured outcomes are:
– Rate of COVID-19 complications (30 day)
– Rate of ICU admission (30 day)
– Rate of mechanical ventilation / O2 requirement (30 day)
– Rate of relapse or progression of hematologic disease (30, 90 and 180 day)
– Overall survival (30, 90 and 180 day)
– Putative risk factors for the severity and lethality of COVID-19 (30, 90 and 180 day)
Objectives of the Study:
Principal Objective: The objective of the study is determine the treatment outcomes in patients with hematologic diseases and COVID-19.
(1) Describe the clinical course of COVID-19 in patients with hematologic disease.
(2) Determine the course and outcomes of hematologic disease in SARS-CoV-2 infected patients.
(3) Explore putative risk factors for the severity and lethality of COVID-19.
More about this Study:
CHRONOS19 is a web-based registry. After registration, physicians from hematology clinical centers and hospitals in Russia will receive access to the web platform for clinical trial management to fill in the online data collection form in a de-identified manner. This form includes questions about general clinical history of hematologic disease, manifestation, treatment, and the course of COVID-19, concomitant conditions, consequences on the hematologic disease, short-term and long-term outcomes. It will take approximately 10 min to answer the questions. Patients will be followed for 30 days after COVID-19 diagnosis and up to 6 months for hematologic disease outcomes and overall survival assessment.
Other Clinical Trials:
This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.
Collaborez avec l’étude ANTICOV et contribuez à traiter la COVID-19 en Afrique.
A study to determine if influenza vaccination or ACEI or ARB medication has effects on COVID-19.
Est-ce que les hormones sexuelles peuvent aider les hommes survivre le COVID-19 ? Cette étude a pour objectif évaluer la sécurité et l’efficacité de la progestérone dans le traitement de COVID-19 chez les hommes hospitalisés.
Open, randomized, adaptive, phase III clinical trial study to evaluate the efficacy of various pharmacological alternatives in the treatment of severe infection in COVID-19 pediatric patients.
Clinical trial designed to determine if the vaccine candidate, AZD1222, can prevent symptomatic COVID-19.
Can hydroxychloroquine (HCQ) safely prevent infection and severe complications in pregnant women? This study focues on prevent COVID-19 during pregnancy.